LRMR
Larimar Therapeutics Inc
NASDAQ: LRMR · HEALTHCARE · BIOTECHNOLOGY
$4.06
-6.45% today
Updated 2026-04-30
Market cap
$461.24M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-2.27
Dividend yield
—
52W range
$2 – $6
Volume
5.0M
Larimar Therapeutics Inc (LRMR) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
0.00%
ROE
-132.60%
ROA
-62.30%
Debt/equity
0.03x
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2011 | — | $-13.16M | — | — | — |
| 2012 | — | $-13.88M | — | — | — |
| 2013 | — | $-14.03M | — | — | — |
| 2014 | — | $-36.57M | — | — | — |
| 2015 | — | $-74.29M | — | — | — |
| 2016 | — | $-57.88M | — | — | — |
| 2017 | — | $-52.03M | — | — | — |
| 2018 | — | $-61.37M | — | — | — |
| 2019 | $0.00 | $-23.13M | — | — | — |
| 2020 | $0.00 | $-42.33M | — | — | — |
| 2021 | $0.00 | $-50.31M | — | — | — |
| 2022 | $0.00 | $-34.18M | — | — | — |
| 2023 | $0.00 | $-36.95M | — | — | — |
| 2024 | $0.00 | $-80.60M | — | — | — |
| 2025 | $0.00 | $-165.67M | — | — | — |